BTK Inhibitors in Cancer Patients with COVID-19: â€œTo Controls That Chaosâ€•(Napoleon Bonaparte)

Clinical Cancer Research

26, 3514-3516

DOI: 10.1158/1078-0432.ccr-20-1427

Citation Report

#	Article	IF	Citations
1	Host-pathogen interaction in COVID-19: Pathogenesis, potential therapeutics and vaccination strategies. Immunobiology, 2020, 225, 152008.	1.9	65
2	Outcomes of COVID-19 in patients with CLL: a multicenter international experience. Blood, 2020, 136, 1134-1143.	1.4	248
3	Drugs targeting various stages of the SARS-CoV-2 life cycle: Exploring promising drugs for the treatment of Covid-19. Cellular Signalling, 2020, 74, 109721.	3.6	105
4	Management of Patients With Hematologic Malignancies During the COVID-19 Pandemic: Practical Considerations and Lessons to Be Learned. Frontiers in Oncology, 2020, 10, 1439.	2.8	26
5	COVID-19: The Impact in Oncology Care. SN Comprehensive Clinical Medicine, 2020, 2, 2621-2630.	0.6	4
6	How We Manage Patients With Chronic Lymphocytic Leukemia During the SARSâ€CoVâ€2ÂPandemic. HemaSphere, 2020, 4, e432.	2.7	18
7	Clinical, inflammatory, and immune differences between COVID-19 patients with and without cancer. Medicine (United States), 2020, 99, e23015.	1.0	1
8	Relevance of the Bruton Tyrosine Kinase as a Target for COVID-19 Therapy. Molecular Cancer Research, 2021, 19, 549-554.	3.4	17
9	The Longitudinal Immune Response to Coronavirus Disease 2019: Chasing the Cytokine Storm. Arthritis and Rheumatology, 2021, 73, 23-35.	5.6	47
10	Recent Developments in the Use of Kinase Inhibitors for Management of Viral Infections. Journal of Medicinal Chemistry, 2022, 65, 893-921.	6.4	24
11	Ibrutinib interferes with innate immunity in chronic lymphocytic leukemia patients during COVID-19 infection. Haematologica, 2021, 106, 2265-2268.	3.5	6
12	PROTAC-Mediated Degradation of Brutonâ€™s Tyrosine Kinase as a Therapeutic Strategy for Cancer. ACS Medicinal Chemistry Letters, 2021, 12, 688-689.	2.8	4
13	Brutonâ€™s tyrosine kinase: an emerging targeted therapy in myeloid cells within the tumor microenvironment. Cancer Immunology, Immunotherapy, 2021, 70, 2439-2451.	4.2	19
14	Impact of COVID-19 in patients with lymphoid malignancies. World Journal of Virology, 2021, 10, 97-110.	2.9	11
15	Reining in BTK: Interdomain Interactions and Their Importance in the Regulatory Control of BTK. Frontiers in Cell and Developmental Biology, 2021, 9, 655489.	3.7	7
16	Btk Inhibitors: A Medicinal Chemistry and Drug Delivery Perspective. International Journal of Molecular Sciences, 2021, 22, 7641.	4.1	30
17	Management of patients with chronic lymphocytic leukemia during the SARSâ€˜CoVâ€˜2 pandemic (Review). Oncology Letters, 2021, 22, 636.	1.8	4
18	The role of Bruton's tyrosine kinase in the immune system and disease. Immunology, 2021, 164, 722-736.	4.4	41

#	Article	IF	Citations
19	Balancing Potential Benefits and Risks of Bruton Tyrosine Kinase Inhibitor Therapies in Multiple Sclerosis During the COVID-19 Pandemic. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	6.0	9
20	Cellular and Molecular Immunology Approaches for the Development of Immunotherapies against the New Coronavirus (SARS-CoV-2): Challenges to Near-Future Breakthroughs. Journal of Immunology Research, 2020, 2020, 1-21.	2.2	6
21	Evaluation of COVID-19 vaccine response in patients with cancer: An interim analysis. European Journal of Cancer, 2021, 159, 259-274.	2.8	50
22	Myricetin exhibit selective anti-lymphoma activity by targeting BTK and is effective via oral administration in vivo. Phytomedicine, 2021, 93, 153802.	5.3	7
23	Clinical Trials of the BTK Inhibitors Ibrutinib and Acalabrutinib in Human Diseases Beyond B Cell Malignancies. Frontiers in Oncology, 2021, 11, 737943.	2.8	13
24	Bruton's Tyrosine Kinase: A Promising Target for the Treatment of COVID-19. Tanaffos, 2020, 19, 85-88.	0.5	6
25	Races of small molecule clinical trials for the treatment of COVIDâ€19: An upâ€toâ€date comprehensive review. Drug Development Research, 2022, 83, 16-54.	2.9	13
26	The Possible Role of Bruton Tyrosine Kinase Inhibitors in the Treatment of COVID-19: A Review. Current Therapeutic Research, 2022, 96, 100658.	1.2	12
27	The Role of Brutonâ€™s Kinase Inhibitors in Chronic Lymphocytic Leukemia: Current Status and Future Directions. Cancers, 2022, 14, 771.	3.7	35
28	Potential therapeutic approaches for targeted inhibition of inflammatory cytokines following COVID-19 infection-induced cytokine storm. Interface Focus, 2022, 12, 20210006.	3.0	16
29	The Development of BTK Inhibitors: A Five-Year Update. Molecules, 2021, 26, 7411.	3.8	29
30	Brutonâ€™s Kinase Inhibitors for the Treatment of Immunological Diseases: Current Status and Perspectives. Journal of Clinical Medicine, 2022, 11, 2807.	2.4	23
31	Recent clinical findings on the role of kinase inhibitors in COVID-19 management. Life Sciences, 2022, 306, 120809.	4.3	10
32	Chinese expert consensus on oral drugs for the treatment of mature B-cell lymphomas (2020 edition). Frontiers of Medicine, 2022, 16, 815-826.	3.4	1
33	Small molecules in the treatment of COVID-19. Signal Transduction and Targeted Therapy, 2022, 7, .	17.1	42
35	Targeting B Cells and Microglia in Multiple Sclerosis With Bruton Tyrosine Kinase Inhibitors. JAMA Neurology, 2023, 80, 404.	9.0	9